Wall Street analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to announce sales of $1.69 million for the current quarter, according to Zacks. Two analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.88 million and the lowest estimate coming in at $1.50 million. Tetraphase Pharmaceuticals posted sales of $1.24 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 36.3%. The company is expected to issue its next earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $1.69 million for the current financial year, with estimates ranging from $6.00 million to $7.11 million. For the next financial year, analysts forecast that the company will post sales of $5.84 million per share, with estimates ranging from $5.00 million to $7.51 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 60.55% and a negative net margin of 1,932.24%. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.46 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The firm’s revenue for the quarter was down 24.5% compared to the same quarter last year.

Several analysts have issued reports on TTPH shares. Stifel Nicolaus increased their target price on shares of Tetraphase Pharmaceuticals from $5.00 to $7.00 and gave the stock a “hold” rating in a research note on Thursday, March 9th. BMO Capital Markets upgraded shares of Tetraphase Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $6.00 to $10.00 in a research note on Friday, March 10th. Finally, Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 14th.

Tetraphase Pharmaceuticals (TTPH) opened at 7.59 on Wednesday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The stock’s 50 day moving average is $7.44 and its 200 day moving average is $6.29. The company’s market capitalization is $288.09 million.

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Tetraphase Pharmaceuticals during the fourth quarter valued at about $156,000. Federated Investors Inc. PA boosted its stake in Tetraphase Pharmaceuticals by 1.0% in the fourth quarter. Federated Investors Inc. PA now owns 130,809 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 1,326 shares in the last quarter. State Street Corp boosted its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 15,931 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Tetraphase Pharmaceuticals by 580.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 226,222 shares of the biopharmaceutical company’s stock valued at $912,000 after buying an additional 192,972 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/06/21/tetraphase-pharmaceuticals-inc-ttph-expected-to-announce-quarterly-sales-of-1-69-million.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.